Effect of guar intake on plasma somatostatin-like immunoreactivity in diabetic patients. 1982

R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama

Addition of diet fiber to meals is reported to result in significant reduction of postprandial glucose levels in diabetic patients as well as in normal subjects. In the present study effect of guar intake (12 g) on plasma somatostatin-like immunoreactivity (SRIF-LI) was studied in non-insulin dependent diabetes (NIDDM) and in insulin-dependent diabetes (IDDM) to see if somatostatin plays a role in reducing postprandial glucose. In 6 of 7 normal controls plasma SRIF-LI increased and reached a maximum at 30 min after guar intake. In 5 of 7 NIDDM patients SRIF-LI reached a maximum at 90 min after guar intake, while in five IDDM patients SRIF-LI significantly decreased through 120 min after guar intake. These results suggest the possibility that guar induced somatostatin secretion contributes to reduction of postprandial glucose levels at least in NIDDM patients as well as in normal subjects, for somatostatin is reported to inhibit glucose uptake from gastrointestinal tract.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004043 Dietary Fiber The remnants of plant cell walls that are resistant to digestion by the alimentary enzymes of man. It comprises various polysaccharides and lignins. Fiber, Dietary,Roughage,Wheat Bran,Bran, Wheat,Brans, Wheat,Dietary Fibers,Fibers, Dietary,Roughages,Wheat Brans
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
July 1978, Clinica chimica acta; international journal of clinical chemistry,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
September 1979, Endocrinology,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
December 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
June 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
January 1998, Journal of endocrinological investigation,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
January 1979, Endocrinology,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
December 1978, The Journal of clinical investigation,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
March 1982, Diabete & metabolisme,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
December 1978, Endocrinology,
R Shimoyama, and S Uehara, and Y Itagaki, and S Izumiyama, and A Hirayama
June 1977, Diabete & metabolisme,
Copied contents to your clipboard!